Wat-Not Staff
Frontline fulvestrant is combined with palbociclib to find a result on breast cancer, According to the first analysis trial from 2020 European Society of Medical Oncology, significant improvement has been found at 1-year comparison of fulvestrant with placebo alone in patients with endocrine-sensitive hormone receptor-positive, HER2- negative metastatic breast cancer met the primary endpoint at the phase 2 FLIPPER trial.
Fulvestrant And Palbociclib: Significant Improvement
Previously it has been found that Fulvestrant and Palbociclib were best in the treatment of patients with HR-positive, HER2-negative metastatic breast cancer. As per new findings, they have progressed on prior endocrine therapy based on the results of the phase 3 PALAMA- fulvestrant alone.
“The combination of palbociclib plus exemestane plus leuprolide showed a consistent significant improvement in PFS compared to the capecitabine arm” Statement by Yeon Hee Park, MD, PhD, from Samsung Medical Center, Sungkyunkwan University, Seoul, South Korea.
What Is A FLIPPER?
Flipper is a randomized, multicenter, double-blind international trial. Flipper enrolled women positive with postmenopausal, had HR- positive, HER2- negative metastatic breast cancer, endocrine-sensitive disease. Flipper trial finds the benefit of palbociclib to fulvestrant in the first-line setting in patients with HR- positive, HER2- negative metastatic breast cancer and including with endocrine- sensitive disease.
Test Results
A total of 211 women were involved in the analysis. It has been found that out of 211; 85,78,48 patients received Palbociclib in the first, second, third or later line setting respectively. The results found that 46 patients achieved partial response while 145 patients experienced stable disease, with an ORR of 21.8% and a disease control rate of 90.5%. Following the median for 14.3 months, median PFS was 12.2 months, the median overall survival was not reached.
Early Palbociclib initiation, sensitivity and acquired resistance to endocrine therapy, estrogen receptor and progesterone receptor double positivity, less than 3 metastatic sites, without visceral metastasis, bone metastasis only, with no prior chemotherapy or endocrine therapy were linked with a prolonged PfS in MBC. The most common nonhematologic AE was fatigue and no patient experienced that leading to the discontinuation.
Conclusion
Palbociclib combined with Endocrine therapy has shown significant benefits in the treatment of breast cancer, including in hormone receptor positive, human epidermal growth factor receptor 2- negative advanced or metastatic breast cancer. This combination is generally tolerable with less side effects, delaying the disease’s progression. It gives patients a sense of relief and control over the disease. In addition delays the need of Chemotherapy and its side effects related to it ,affecting their day to day life.
GIPHY App Key not set. Please check settings